Sreeram Ramagopalan

Ram has held senior leadership positions at major pharmaceutical companies where he led teams developing market access strategies for the blockbuster oncology treatments, spearheaded innovative outcomes-based agreements for rare disease assets, and leveraged strategic evidence generation to drive market share and revenue growth.

Ram maintains active involvement in shaping industry practices through collaborations with HTA agencies like NICE and regularly contributes to the Journal of Comparative Effectiveness Research on HTA and Real World Evidence.